Antiphospholipid Syndrome and Autoimmune Coagulation
Antiphospholipid syndrome (APS) is an autoimmune thrombophilic disorder characterized by recurrent thrombosis and pregnancy complications from antiphospholipid antibodies that promote clot formation. Environmental triggers including PFAS may contribute to autoantibody development in susceptible individuals.
PFAS and Phospholipid Binding Protein Disruption
PFAS compounds interact with phospholipid-binding proteins including beta-2 glycoprotein I and prothrombin—the primary targets of antiphospholipid antibodies. PFAS binding may induce conformational changes in these proteins that expose cryptic epitopes, triggering autoantibody production in genetically vulnerable individuals.
Pregnancy Loss Mechanistic Overlap
APS causes recurrent miscarriage through placental thrombosis and complement activation impairing trophoblast function. PFAS-exposed women show higher rates of pregnancy complications through partially overlapping mechanisms—impaired trophoblast invasion, placental dysfunction, and immune activation—suggesting potential synergy between PFAS exposure and APS in reproductive outcomes.
Hematology and Obstetric Practice
Hematologists and maternal-fetal medicine specialists evaluating antiphospholipid syndrome should include environmental PFAS exposure assessment. Women with positive antiphospholipid antibodies and PFAS contamination history may benefit from enhanced monitoring during pregnancy and consideration of PFAS reduction strategies.